Only two months after Shire plc shelled out $750 million in cash for Advanced BioHealing Inc. – a move hailed as a rare win for investors in the regenerative medicine space – the big pharma reported disappointing data from a pivotal trial aimed at expanding the use of ABH's lead product Dermagraft.